Alltrna, a tRNA biology biotech, is cutting 34% of its 55-person workforce as it accelerates toward clinical trials. This is a common biotech pattern: as a company moves from broad research to focused clinical development, it sheds the scientific staff that supported earlier-stage exploration.
At 19 people affected, this is one of the smallest cuts tracked in 2026. But for a 55-person company, losing a third of the team fundamentally changes the organization. The remaining staff will carry significantly more responsibility as the company narrows its focus.